14.09USD-1.57%Mkt Cap: 30.93M USDP/E: —Last update: 2026-05-22
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The comp…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap30.93M USD
Enterprise Value28.79M USD
Revenue (TTM)8.84M USD
Gross Profit8.84M USD
Net Income (TTM)-10.94M USD
Revenue/Share6.115 USD
Last Price14.09 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.01
PEG—
EV/EBITDA-3.17
EV/Revenue3.26
P/S3.55
P/B-9.64
EPS (TTM)-7.57
EPS (Forward)-0.65
52W Range
3.65927% of range42.12
52W High42.12 USD
52W Low3.659 USD
Profitability
Gross Margin100.00%
Oper. Margin431.87%
EBITDA Margin-102.75%
Profit Margin-128.69%
ROE343.13%
ROA-162.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.37M USD
CapEx (TTM)—
FCF Margin-110.93%
FCF Yield-31.71%
Net Debt-2.63M USD
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity-0.20
Current Ratio0.96
Quick Ratio0.91
Book Value/Sh-1.4850 USD
Cash/Share1.492 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateNov 25, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.20M
Float1.19M
Insiders53.32%
Institutions0.03%
Short Interest
Short Ratio0.3d
Short % Float0.24%
Short % Out.0.12%
Shares Short2.69K
Short (prev mo.)8.56K
Technical
SMA 5015.47 (-8.9%)
SMA 20016.21 (-13.1%)
Beta1.52
S&P 52W Chg28.31%
Avg Vol (30d)5.96K
Avg Vol (10d)8.42K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—